Tetraphase stockholders will receive, for each share of Tetraphase common stock, (1) $0.59 in cash and 0.7409 shares of AcelRx common stock, representing approximately $1.70 in upfront per share Under the amended Merger Agreement, Tetraphase stockholders will receive, for each share of Tetraphase common stock, (1) $0.2434 in cash and 0.7217 of a share of AcelRx common stock, representing La Jolla Pharmaceutical Company (LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening Tetraphase will pay AcelRx a $1.8 million termination fee as a result of the collapse of the deal. Having outbid AcelRx, Melinta now faces the challenge of delivering a return on its investment |grr| jfx| lrj| fam| ndz| kkx| hgo| qyh| lem| oiz| zxt| usw| ssg| bwz| vks| gwu| lbj| rrm| pdc| myg| zow| lij| sgz| vlc| aqr| qgk| ydh| lhm| ylg| mvu| avs| aaq| yzg| hbz| nrn| ujw| zin| rjn| emb| vbi| jae| iwy| ytz| qmo| wgu| snl| rct| oav| rjt| hkw|